Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C, Chronic
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
This single arm study will evaluate the efficacy and safety of PEGASYS (180 micrograms sc weekly) plus ribavirin (1000-1200mg po daily) in treatment-naive Latino patients versus non-Latino Caucasian patients with chronic…
- Trial name
- NCT00107653
- Testing
- Ribavirin, Peginterferon alfa-2a
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 569 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Substance Abuse, Intravenous
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Previous intravenous drug abusers with chronic hepatitis C who are under substitution therapy (buprenorphine, methadone) will be treated with PegIntron and Rebetol according to the approved European labeling.
- Trial name
- SUPPORT (NCT00726557)
- Testing
- PegIntron (pegylated interferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 246 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
The aim of this study is to investigate the efficacy and safety of an insulin-sensitizer (Actos) added to a standard Pegasys/Copegus combination therapy of chronic hepatitis C in patients who have previously failed a…
- Trial name
- NCT00433069
- Testing
- Pioglitazone, Interferon Alfa-2a, Ribavirin
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- University Hospital, Geneva
Hepatitis C, Chronic
ATTIC - Access To Treat in the Community
The study is looking at the potential of utilizing a "point of care" test and treat pathway; using the DDA called Zepatier for achieving SVR in an homeless population who have tested positive for genotype 1 or 4 HCV.
- Trial name
- ATTIC (NCT03797066)
- Testing
- ZEPATIER 50Mg-100Mg Tablet
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- King's College Hospital NHS Trust
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00217139
- Testing
- Celgosivir
- Where
- 6 sites in Canada
- Volunteers
- 60 people
- Sponsor
- BioWest Therapeutics Inc
Chronic Hepatitis C
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin…
- Trial name
- REAL (NCT02582658)
- Volunteers
- 173 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)
This study will compare the efficacy and safety of treatment with pegylated-interferon alfa-2a plus ribavirin in participants with non-genotype 2/3 CHC who, after 12 weeks of study treatment, have undetectable hepatitis C virus…
- Trial name
- IMPROVE (NCT00483938)
- Testing
- Pegylated-interferon Alfa-2a, Ribavirin
- Where
- 23 sites in United States, Canada
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (PegIntron®/peg-IFN) and ribavirin (RBV) in chronic hepatitis C (CHC) Genotype I…
- Trial name
- NCT01405937
- Testing
- vaniprevir, peg-IFN, ribavirin
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients
The main objective of antiviral therapy of patients with chronic hepatitis C (CHC) is the sustained elimination of the hepatitis C virus (HCV).
- Trial name
- NCT01197157
- Testing
- Nitazoxanide
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis C, Chronic
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients…
- Trial name
- NCT01399619
- Testing
- PegIFN/RBV, BI201335, BI201335 24W
- Where
- 71 sites in United States, Brazil and 6 more
- Volunteers
- 310 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic genotype 1, 2, 4, 6 or indeterminate HCV infection who…
- Trial name
- NCT02346721
- Testing
- SOF/VEL
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Acute Hepatitis C
Treatment of Recently Acquired Hepatitis C Virus Infection
To determine whether response guided treatment with pegylated interferon +/- ribavirin is effective for the treatment of recently acquired hepatitis C infection.
- Trial name
- ATAHC-II (NCT01336010)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in Australia
- Volunteers
- 82 people
- Sponsor
- Kirby Institute
End Stage Renal Disease, Chronic Hepatitis c
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive…
- Trial name
- NCT04614142
- Testing
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Human Immunodeficiency Virus, Hepatitis B, Chronic
Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
The purpose of this study is to compare the liver toxicity in HIV-infected patients with chronic hepatitis B and/or hepatitis C, who start a new antiretroviral drug regimen, as well as the influence of the degree of pre-existing…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic
- Trial name
- NCT01908660
- Testing
- antiretroviral drugs
- Where
- Spain
- Volunteers
- 192 people
- Sponsor
- Valme University Hospital
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and…
- Trial name
- PRINCIPAL (NCT01616524)
- Testing
- Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin
- Where
- 124 sites in United States, Argentina and 17 more
- Volunteers
- 880 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection
No more than 56% of subjects at the Robley Rex Louisville Veterans Administration Medical Center (VAMC) prescribed boceprevir-based triple therapy, will complete Hepatitis C (HCV) treatment as prescribed.
- Trial name
- NCT02070107
- Testing
- On Plan
- Where
- United States
- Sponsor
- University of Louisville
Hepatitis C, Chronic
A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C
This randomized, open-label, multi-center study will evaluate the sustained virological response, pharmacokinetics and safety of various combinations of danoprevir/ritonavir with Copegus plus RO5024048 and/or Pegasys in patients…
- Trial name
- NCT01331850
- Testing
- Copegus, Pegasys, RO5024048
- Where
- 67 sites in United States, Australia and 11 more
- Volunteers
- 381 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
To explore the effect on early viral kinetics and viral load, and to determine safety, tolerability and anti-viral response for the plasmid DNA vaccine CHRONVAC-C administered i.m.
- Trial name
- NCT01335711
- Testing
- ChronVac-C + SOC, SOC
- Where
- 2 sites in Sweden
- Volunteers
- 32 people
- Sponsor
- ChronTech Pharma AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.